ISSN- 2230-7346
Journal of Global Trends in Pharmaceutical Sciences

INTEGRATING NOVEL BIOMARKERS, PATIENT ADVOCACY, AND OPEN ACCESS IN DECENTRALIZED CLINICAL TRIALS: NAVIGATING CHALLENGES FOR INFECTIOUS DISEASES AND RARE DISEASES RESEARCH

Vivek Reddy M*, Pratheksha S, Vaishnavi Parimala Thumpati, Gokul shree, Sanjay S, Sanjeev RN, Rakshan T, Sanaulla S, GNK Ganesh

Department of Regulatory Affairs, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Ooty, Tamil Nadu, INDIA.

*Corresponding author E- mail: vivekpharmacon@gmail.com

ARTICLE INFO

Key words:
Clinical Trials, Ethics, Biomarkers, Infectious Diseases, Rare diseases

Access this article online
Website: https://www.jgtps.com/
Quick Response Code:

ABSTRACT

Clinical trials in infectious and rare diseases provide complex hurdles ranging from practical challenges to ethical issues. This research investigates new strategies to overcoming these barriers, including novel biomarkers, patient advocacy, and open access in decentralized clinical trials (DCTs). Biomarkers, which are essential in clinical research, provide insights into patient status, pharmacokinetics, and therapy effectiveness, revolutionizing trial design. The incorporation of patient advocacy groups (PAGs) appears as a critical technique for addressing the unique viewpoints and ethical concerns in infectious and uncommon illnesses. Open access in clinical trials, along with the advent of DCTs, improves openness and cooperation, but ethical issues must be carefully addressed. This paper examines biomarker used in the real world, PAGs' expanding role, the history of open access, and the influence of technical advancements on trial procedures. The discussion part goes into the problems and opportunities presented by DCTs, patient-centered trial designs, and the possible future landscape of clinical research. The predictions of a patient-centric future based on these integrated techniques, with breakthroughs and fair outcomes in clinical trials for all populations.

INTRODUCTION

The burden of infectious diseases and rare diseases is high, especially in areas with limited resources.[1] Conducting effective clinical trials in these settings presents significant challenges ranging from logistical barriers such as geographic barriers to ethical concerns related to patient access and data sharing.[2] However, recent advances in collaborative technologies and methods offer promising solutions to transform clinical research and improve health outcomes for vulnerable populations.[3] For rare diseases, trial design and delivery can be complicated by the need for multicenter trials, design protocols, ethical reviews, and cultural diversity. Considering how these diseases diversity and complexity, endpoint choice in rare disease trials is important.[4] For infectious diseases, clinical orphan drug trials have small sample sizes, early approval, and non-randomized and blinded designs. Times of infectious diseases may vary, with tuberculosis having the longest delay in stage I or III International coordination is essential to facilitate patient recruitment and ensure that research findings in rare disease trials are published in time in a proper manner.[5]

Novel biomarkers play an important role in clinical trials across medicine by providing

information on patient status, pharmacokinetics, efficacy, and safety.[6] They can also be used as surrogates for drug approvals, replacing direct determination of treatment endpoints.[7] The use of biomarkers in clinical trials has increased, resulting in efforts to standardize their labeling, assessment, and validation.[8] Biomarkers are measured using a variety of methods, including proteomic and genomic approaches . These biomarkers are applied to a variety of diseases, and more than 3000 biomarkers have been identified in 2600 diseases.[9] Recent technological advances in instrumentation and data computation have facilitated biomarker discovery and development. Overall, the new biomarkers have the potential to improve clinical trials, drug screening and patient care with improved efficacy and effectiveness.[10]

Decentralized clinical trials (DCTs) are participant-centered approaches that use new technologies and methodologies in clinical trials outside of centralized clinical research sites.[11] DCTs aim to reduce burden on users increase their participation, especially those with rare diseases or infectious diseases, by allowing them to participate at home.[12] Ethical considerations exist when implementing decentralized clinical trials (DCTs) for infectious diseases and rare diseases.[13] While DCT offers advantages such as greater access to patients regardless of location, removal of logistical barriers, and inclusion of diverse populations, ethical implications there is much to consider. These include impacts on patient-healthcare professional relationships, patient-social issues, data integrity, personal data security, and risks to health and safety DCTs require a dedicated system , appropriate professional and regulatory frameworks.[14] Ethics committee (EC) reviews are crucial for the ethical assessment of DCTs, requiring the use of appropriate assessment tools and regulatory frameworks.[15] Biologists have paid little attention to DCT, emphasizing the importance of ethical considerations in this rapidly growing field. DCT can improve screening for rare infectious diseases, but ethical implications must be carefully considered.[16]

1. NOVEL BIOMARKERS

Biomarkers are measurable properties or physiological characteristics that indicate the presence or progression of a biological process, condition, or disease.[17] In clinical trials, biomarkers can provide valuable information about the efficacy and safety of potential treatment interventions. For example, biomarkers can be used to identify patients who are likely to respond to a particular treatment, monitor response to treatment over time, monitor disease progression or the effect of treatment on patients.[18] Biomarkers in infectious diseases can help to identify, establish and predictive display. The discovery of novel biomarkers used for clinical trials is a long process and takes about a year for the discovery (Fig.1).[19] Biomarkers are distinct from clinical outcome measures, which measure outcomes of direct patient importance, such as mood, function, or survival.[20] Biomarkers (Table 1) play an important role in clinical trials for infectious diseases and rare diseases. They can help researchers better understand the pathophysiology of the disease, identify appropriate patient populations for clinical trials, and measure response to treatment. Challenges of Biomarkers in Infectious Diseases and Rare Diseases pose many challenges to the use of Biomarkers in clinical trials. One of the major challenges is the identification and validation of relevant biomarkers.[21]

1.1 Real-world Applications of Novel Biomarkers

Dengue & Chikungunya - Point-of-care NS1 assay: Point-of-care NS1 tests are critical for early Dengue detection and monitoring. They use particular antibodies to identify dengue virus NS1.[22] Several studies have developed and assessed several NS1 assays, including ELISA and fast diagnostic procedures, with some demonstrating increased sensitivity when paired with IgM detection.



Fig.1 – Process of Discovery of Novel Biomarkers used in Clinical Trails

Table: 1 - Examples of Novel Biomarkers for Infectious Diseases and rare diseases

Disease Category	Biomarker Type	Application	Advantages	Limitations
Dengue & Chikungunya	Point-of-care NS1 assays	Rapid diagnosis at point-of-care, early case management, outbreak surveillance	Affordable, simple, fast results	Sensitivity can vary, potential for false negatives
Malaria	Rapid diagnostic tests (RDTs)	Detection of malaria parasites (e.g., Plasmodium spp.)	Accessible, affordable, quick results	Limited sensitivity for low parasite densities
Human African Trypanosomiasis (Sleeping Sickness)	LAMP (Loop-mediated isothermal amplification) tests	Detection of trypanosomes in blood or lymph	Sensitive, rapid, portable, can be used in field settings	Requires trained personnel, equipment cost

Tuberculosis	GeneXpert® MTB/RIF assay	Detection of Mycobacterium tuberculosis and rifampicin resistance	High sensitivity and specificity, rapid results	Requires specific equipment, higher cost
HIV	Viral load monitoring	Assessing viral replication and response to antiretroviral therapy	Helps guide treatment decisions, improve patient outcomes	Requires laboratory testing, cost can be a barrier
Respiratory Syncytial Virus (RSV)	Multiplex immunoassays	Simultaneous detection of multiple respiratory viruses, including RSV	Differentiates RSV from other respiratory infections, informs treatment	Equipment cost, potential for false positives
Gastrointestinal Infections	Rotavirus antigen tests	Diagnosis of rotavirus gastroenteritis	Simple, rapid, accurate diagnosis	Limited availability in some settings
Neurological Diseases	Genetic sequencing (e.g., whole exome sequencing)	Identification of causative mutations, personalized medicine, early diagnosis	Highly accurate, provides insights into disease mechanisms	Costly, complex data analysis, potential for variants of uncertain significance
Metabolic Disorders	Metabolomics (e.g., mass spectrometry)	Characterization of metabolic derangements, disease monitoring, treatment response prediction	Non-invasive, broad metabolic picture, potential for early detection	Requires specialized equipment, complex data interpretation
Muscular Dystrophies	Muscle biopsy with immunohistochemistry	Detection of specific protein abnormalities, disease subtype classification, prognostic assessment	Direct visualization of muscle pathology, high accuracy	Invasive procedure, limited accessibility, time-consuming
Autoimmune Diseases	Autoantibody panels (e.g., ELISA)	Identification of specific autoantibodies, diagnosis confirmation, disease subtype differentiation	Relatively simple, accessible tests, high specificity for certain disorders	Limited coverage of potential autoantibodies, potential for false positives
Cancer (Rare	Circulating tumor DNA	Early detection of	Non-invasive,	Technical challenges

Cancers)	(ctDNA)	disease recurrence, tumor monitoring, treatment response assessment	highly sensitive for specific mutations	in low ctDNA levels, potential for inconclusive results

Table : 2 - The Expanding Role of Patient Advocacy in Shaping Clinical Trials

Trend	Impact
Increased use of technology (e.g., online platforms, data sharing tools)	Improved communication and collaboration between PAGs and researchers
Focus on patient-reported outcomes and quality of life measures	More patient-centred trial designs and endpoints
Growth of personalized medicine and targeted therapies	Increased emphasis on patient advocacy in biomarker development and precision medicine research
Emphasis on ethical considerations and patient safety in research	Enhanced protection of patient rights and well-being in clinical trials
Greater collaboration between PAGs, researchers, and policymakers	Development of more effective and equitable clinical trial systems for all patients

Table 3: Evolution of Open Access and Decentralized Clinical Trials (DCTs)

Year	Open Access	Decentralized Clinical Trials (DCTs)	Potential Impact (Combined)
1960s		Early use of home monitoring in trials	
1970s	Budapest Open Access Initiative		
1980s	Rise of internet and online journals		
1990s	Public Library of Science (PLOS) launched	Advancements in telemedicine and communication technologies	Increased access to knowledge
2000s	Growth of open access journals	DCTs gain traction due to rising drug development costs	Improved recruitment and representation
2010s	Berlin Declaration on Open Access	COVID-19 pandemic accelerates DCT adoption	Real-time data collection and monitoring
2020s	Plan S mandates open access for funded research	Increased use of digital tools and technologies in DCTs	More efficient and cost-effective research

NS1 may be identified in a variety of samples, and microfluidic technologies provide a quick testing method. Protein coronas have been shown to alter detection limits and affinity in NS1 immunoassays.[23]

Neurological Diseases - Genetic Sequencing (Whole Exome Sequencing: Whole exome sequencing (WES) is a genetic sequencing approach that focuses on sequencing the exome, or the region of the genome that includes protein-coding

genes.[24] It is a thorough strategy that enables the detection of genetic variants that may be responsible for uncommon and complicated genetic diseases. WES has been routinely utilised in clinical settings to diagnose such diseases, yet some individuals still go undetected. In these circumstances, additional approaches like as structural variations, STRs, long read sequencing, pan genomics, proteomics, and transcriptomics can be used to increase diagnostic yield. WES may also be used to identify premalignant genetic progression by sequencing the main tumour. This approach gives useful information on the genetic changes that occur throughout development of cancer.[25]

PATIENT ADVOCACY: Patient advocacy groups (PAGs) are emerging as key contributors to the success of clinical trials, especially in complex cases involving infectious diseases and rare diseases. This review aims to highlight the importance of patient advocacy in clinical research, clarify the unique perspectives that PAGs bring to the table, and their role as a tool to overcome the challenges of trial design, recruitment, ethical considerations, and patient support management.[26] Patient perspectives is a very challenging pace to come across. PAG plays an important role in encapsulating patient experiences and realistic insights into clinical trials. By actively participating in the research process, these organizations ensure that the testing process is responsive to the specific concerns and needs of the patient group. This combination of unique perspectives makes clinical trials more relevant and effective.[27] Ethical considerations in clinical trials are considered very crucial. While advocating for ethics in research, PAGs play an important role in promoting principles such as informed consent, data confidentiality, and participant welfare.[28] Commitment a providing ethical considerations ensures the integrity of clinical trials and builds confidence in both patients and the public. Addressing the challenges of infectious diseases and rare diseases are at high risk. In low-level infectious diseases, where pathogen evolution is rapid, and various immune responses prevail, PAGs contribute to flexible and adaptive testing protocols. Meanwhile, for rare diseases, the challenges of a small number of patients are addressed by supporting patient-centered PAG biomarker approaches to description and test design.[29]

2.1 The future of patient advocacy: As technology advances and the importance of patient involvement is recognized, PAGs are poised to play an increasingly important role in shaping the future of clinical trials. The efforts of these groups continue to advocate ensuring that research remains patient-centered, delivering breakthroughs that will benefit the broadest possible population. It is important to recognize that patient advocacy (Table 2) is more than just participation; It's about empowerment. Giving patients a voice in research leads to success in envisioning a future where clinical trials are truly patient-centered and improve outcomes for everyone. Collaborative efforts by researchers and patient advocacy groups promise a more inclusive and influential era in clinical research.[30]

OPEN ACCESS IN CLINICAL TRAILS

Open Access in clinical trials is the practice of making study findings and data openly available to the public. This increases transparency and accessibility by allowing academics, healthcare professionals, patients, and the general public to view and review clinical trial data. Open Access in clinical trials is critical for assuring openness, eliminating publication bias, and advancing scientific knowledge. Decentralized Clinical Trials is a method of conducting clinical trials that uses digital technology to collect data from study participants in their own environments, such as their homes.[31]

3.1 Emergency of decentralized clinical trials: The introduction of Decentralized Clinical Trials has transformed how clinical trials are done. It has various benefits, including greater patient convenience and engagement, lower costs, and better data collecting. Decentralized clinical trials use digital technology for remote monitoring and data collecting, reducing the requirement for participants to visit to a physical research location. The Impact of Open Access in Decentralized Clinical Trials (Table 3) plays an important role in Decentralized Clinical Trials since it ensures that the data and conclusions generated by these trials are freely available to the public. This increases transparency, makes it easier for academics and stakeholders to collaborate, and enables for more widespread information dissemination.[32]

3.2 Ethics in open access and DCTs: Open access publication presents ethical problems, including discrimination against academics, editorial conflicts of interest, and diverting money away from research.[33] Decentralized clinical trials (DCTs) also have ethical considerations, such as changes to research protocols, a lack of expertise for ethical review of digital tools, different privacy standards, risks to participant privacy and confidentiality, the impact of the digital divide, subject selection bias, new burdens on research subjects and careers, limited access to the study team, and the impact on informed consent.[34] DCTs need specialized infrastructures, appropriate regulatory frameworks, and collaboration among research locations, patients, and sponsors.[35] Ethical review by Ethics Committees is critical for clinical trial innovation and digitalization.[36] DCTs offers benefits such as adjusting to patients' habits, reducing logistical constraints, and encompassing different groups; nevertheless, they also pose ethical concerns about patient-provider interactions, data integrity, personal data security, and health and safety threats.[37] More ethical consideration is required in both open access publishing and DCTs.

3.3 Technological Advances in Clinical Trials

Blockchain technology: Protects clinical trial data with a decentralized, tamper-resistant ledger, improving transparency and preventing manipulation.

Remote Informed Consent Platforms: Using eConsent platforms allows participants to see and sign informed consent papers online, enhancing accessibility, comprehension, and documentation of the process.

Digital biomarkers: Identified and validated using modern imaging technologies such as fMRI and PET, provide objective indicators of illness progression and therapy response.

Virtual Reality (VR) and Augmented Reality (AR) Improve patient involvement by offering immersive experiences for clinical trials, treatments, and illness education. Also applicable for training healthcare professionals involved in clinical trials.

2. DISCUSSION

4.1 Challenges and Opportunities in DCTs

Decentralized Clinical Trials (DCTs) provide revolutionary potential and difficulties as they change from site-centric to participant-centered approaches. Patient-provider interactions, data integrity, personal data protection, and health and safety are all ethical considerations that necessitate the use of specialized systems, regulatory frameworks, and ethics committee oversight. The changing circumstances requires a careful balance between improved patient access and ethical protections.[38]

4.2 Patient-Centered Trial Designs

Patient advocacy groups (PAG) play an important role in designing patient-centered trial designs by actively engaging patients, addressing special issues in infectious and rare illnesses, and arguing for ethical norms to ensure trial integrity.[39]

4.3 Future Landscape of Clinical Research

As technology progresses, patient engagement increases, pointing to a future in clinical research characterized by collaboration among patient advocacy organizations, researchers, and legislators. The use of technology such as blockchain and virtual/augmented reality demonstrates a dedication to innovation, while the emphasis on open access promotes transparency and improves communication between patient advocacy organizations and researchers.[40]

CONCLUSION

The combination of innovative biomarkers, patient advocacy, and open access in decentralized clinical trials provides an effective response to the problems of infectious and rare disease research. Biomarkers improve real-time monitoring and personalized treatment methods, patient advocacy organizations provide valuable insights into trial design, and open access promotes openness and cooperation. Together, these aspects help to make clinical research more successful and inclusive, eventually expanding our understanding of diseases and improving outcomes for various patient populations. This integrated strategy has significant potential for bridging gaps and providing hope to individuals suffering by infectious and uncommon diseases throughout the world.

Acknowledgement: The authors would like to thank the Department of Science and Technology - Fund for Improvement of Science and Technology Infrastructure (DST-FIST) and Promotion of University Research and Scientific Excellence (DST-PURSE) for the facilities provided.

Conflict of interest: Authors don’t have any conflict of interest

REFERENCES

1. Jemima, E., Mellerio. (2022). The challenges of clinical trials in rare diseases. British Journal of Dermatology, doi: 10.1111/bjd.21686
2. P., Kudyar., Mahanjit, Konwar., Zoya, Khatri., Nithya, J, Gogtay., Urmila, M, Thatte. (2022). Evaluation of clinical trials done for orphan drugs versus nonorphan drugs in infectious diseasesan eleven year analysis [2010-2020]. Perspectives in Clinical Research, doi: 10.4103/picr.picr_137_21
3. Piet, H., van, der, Graaf. (2020). Finding New Drugs for Infectious Diseases: Development Times and Success Rates.. Clinical Pharmacology & Therapeutics, doi: 10.1002/CPT.1728
4. Anne, Musters., Sander, W., Tas. (2020). Room for improvement in clinical trials for rare diseases.. Nature Reviews Rheumatology, doi: 10.1038/S41584-020-0376-6
5. (2022). Chapter 3. Clinical Trials in the Development of Vaccines for Infectious Diseases. Drug development and pharmaceutical science, doi: 10.1039/9781839162572-00050
6. Natalie, M., Hendrikse., Jordi, Llinares, Garcia., Thorsten, Vetter., Anthony, J., Humphreys., Falk, Ehmann. (2022). Biomarkers in Medicines Development—From Discovery to Regulatory Qualification and Beyond. Frontiers in Medicine, doi: 10.3389/fmed.2022.878942
7. Janet, Piñero., Pablo, S., Rodriguez, Fraga., Jordi, Valls-Margarit., Francesco, Ronzano., Pablo, Accuosto., Ricard, Lambea, Jane., Ferran, Sanz., Laura, I, Furlong. (2023). Genomic and proteomic biomarker landscape in clinical trials. Computational and structural

biotechnology journal, doi: 10.1016/j.csbj.2023.03.014
8. Diane, Stephenson., Reham, Badawy., Soania, Mathur., Maria, B., Tome., Lynn, Rochester. (2021). Digital Progression Biomarkers as Novel Endpoints in Clinical Trials: A Multistakeholder Perspective.. Journal of Parkinson's disease, doi: 10.3233/JPD-202428
9. (2022). Biomarkers in drug development. doi:10.1016/b978-0-12-819869-8.00029-x
10. Kurtis, J, Swanson., Fahad, Aziz., Neetika, Garg., Maha, Mohamed., Didier, A., Mandelbrot., Arjang, Djamali., Sandesh, Parajuli. (2020). Role of novel biomarkers in kidney transplantation. World journal of transplantation, doi: 10.5500/WJT.V10.I9.230
11. Mercedeh, Ghadessi., Chenkun, Wang., Kiichiro, Toyoizumi., Nan, Shao., Chaoqun, Mei., Charmaine, Demanuele., Rui, Tang., Gianna, McMillan., Robert, A., Beckman. (2023). Decentralized clinical trials and rare diseases: a Drug Information Association Innovative Design Scientific Working Group (DIA-IDSWG) perspective. Orphanet Journal of Rare Diseases, doi: 10.1186/s13023-023-02693-7
12. Federico, Pennestrì., Giuseppe, Banfi., Rossella, Tomaiuolo. (2023). Remote decentralized clinical trials: a new opportunity for laboratory medicine. Clinical chemistry and laboratory medicine, doi: 10.1515/cclm-2022-1184
13. Carlo, Petrini., Chiara, Mannelli., Luciana, Riva., Sabina, Gainotti., Gualberto, Gussoni. (2022). Decentralized clinical trials (DCTs): A few ethical considerations. Frontiers in Public Health, doi: 10.3389/fpubh.2022.1081150
14. (2023). Decentralization of Clinical Trials: Opportunities, Risks and Development Paths. Studies in health technology and informatics, doi: 10.3233/shti230480
15. Alessandro, Venturi., Maria, Rosaria, Iardino. (2023). Decentralization of Clinical Trials: Opportunities, Risks and Development Paths. doi: 10.3233/SHTI230480
16. Adys, Mendizabal., Nora, L., Jones. (2023). Ethical Considerations in Clinical Trials for Rare Genetic Diseases: The Case of Huntington's Disease. American Journal of Bioethics, doi: 10.1080/15265161.2023.2207511
17. Ahmad A, Imran M, Ahsan H. Biomarkers as Biomedical Bioindicators: Approaches and Techniques for the Detection, Analysis, and Validation of Novel Biomarkers of Diseases. *Pharmaceutics*. 2023;15(6):1630. Published 2023 May 31. doi:10.3390/pharmaceutics15061630
18. Hodgson, D. R., Whittaker, R. D., Herath, A., Amakye, D., & Clack, G. (2008). Biomarkers in oncology drug development. Molecular Oncology, 3(1), 24–32. doi:10.1016/j.molonc.2008.12.002
19. Califf RM. Biomarker definitions and their applications. *Exp Biol Med (Maywood)*. 2018;243(3):213-221. doi:10.1177/1535370217750088
20. Jain KK. Role of Biomarkers in Health Care. *The Handbook of Biomarkers*. 2010;115-188. Published 2010 Jan 20. doi:10.1007/978-1-60761-685-6_5
21. Strimbu K, Tavel JA. What are biomarkers?. *Curr Opin HIV AIDS*. 2010;5(6):463-466. doi:10.1097/COH.0b013e32833ed177

22. Pei, Yin, Lim., Appanna, Ramapraba.., Thomas, Loy., Angeline, Rouers., Tun-Linn, Thein., Yee, Sin, Leo., Dennis, R., Burton., Katja, Fink., Cheng-I, Wang. (2023). A nonstructural protein 1 capture enzyme-linked immunosorbent assay specific for dengue viruses. PLOS ONE, doi: 10.1371/journal.pone.0285878
23. diagnostics using Cygnus: Development and evaluation of rapid serotype-specific NS1 detection with dengue patient samples. *PLoS Negl Trop Dis*. 2022;16(4):e0010266. Published 2022 Apr 7. doi:10.1371/journal.pntd.0010266
24. Ahmed, Al-Mandhari., Amal, Barakat., Abdinasir, Abubakar., Richard, J, Brennan. (2022). Genomic sequencing for epidemic and pandemic preparedness and response: EMRO's vision and strategic interventions.. Eastern Mediterranean Health Journal, doi: 10.26719/2022.28.12.851
25. Young-gon, Kim., Hyemi, Kwon., Jong-Oh, Park., Soo, Hyun, Nam., Changhee, Ha., Sung, Tae, Shin., W., Heo., Hye, Jin, Kim., Ki, Wha, Chung., Ja-Hyun, Jang., Jong-Won, Kim., Byung-Ok, Choi. (2023). Whole-genome sequencing in clinically diagnosed Charcot–Marie–Tooth disease undiagnosed by whole-exome sequencing. Brain communications, doi: 10.1093/braincomms/fcad139
26. Patterson AM, O'Boyle M, VanNoy GE, Dies KA. Emerging roles and opportunities for rare disease patient advocacy groups. *Ther Adv Rare Dis*. 2023;4:26330040231164425. Published 2023 Apr 24. doi:10.1177/26330040231164425
27. Merkel, P.A., Manion, M., Gopal-Srivastava, R. *et al.* The partnership of patient advocacy groups and clinical investigators in the rare diseases clinical research network. *Orphanet J Rare Dis* **11**, 66 (2016). https://doi.org/10.1186/s13023-016-0445-8
28. Muthuswamy V. Ethical issues in clinical research. *Perspect Clin Res*. 2013;4(1):9-13. doi:10.4103/2229-3485.106369
29. What is ethics in research and why is it important? National Institute of Environmental Health Sciences. Accessed February 17, 2024. https://www.niehs.nih.gov/research/resources/bioethics/whatis.
30. Stoumpos AI, Kitsios F, Talias MA. Digital Transformation in Healthcare: Technology Acceptance and Its Applications. *Int J Environ Res Public Health*. 2023;20(4):3407. Published 2023 Feb 15. doi:10.3390/ijerph20043407
31. Modi ND, Kichenadasse G, Hoffmann TC, et al. A 10-year update to the principles for clinical trial data sharing by pharmaceutical companies: perspectives based on a decade of literature and policies. *BMC Med*. 2023;21(1):400. Published 2023 Oct 23. doi:10.1186/s12916-023-03113-0
32. Hanley DF Jr, Bernard GR, Wilkins CH, et al. Decentralized clinical trials in the trial innovation network: Value, strategies, and lessons learned. *J Clin Transl Sci*. 2023;7(1):e170. Published 2023 Jul 25. doi:10.1017/cts.2023.597
33. Carlo, Petrini., Chiara, Mannelli., Luciana, Riva., Sabina, Gainotti., Gualberto, Gussoni. "Decentralized clinical trials (DCTs): A few ethical considerations." Frontiers in Public Health, undefined (2022). doi: 10.3389/fpubh.2022.1081150

34. Assya, Pascalev. "191 Ethical Considerations of Decentralized Clinical Trials." Journal of clinical and translational science, undefined (2022). doi: 10.1017/cts.2022.95
35. Miguel, Castañeda., Jose, Texier., Analia, Mercado. "Ethical considerations on the relationship between Open Access and scientific quality in Engineering." undefined (2020).
36. Nerissa, Lindsey., Greta, Kuriger, Suiter., Kurt, Hanselman. "Ethical Considerations of Including Personal Demographic Information in Open Knowledge Platforms." KULA, undefined (2022). doi: 10.18357/kula.228
37. David, Shaw., Bernice, Simone, Elger. "Unethical aspects of open access." Accountability in Research, undefined (2018). doi: 10.1080/08989621.2018.1537789
38. Petrini C, Mannelli C, Riva L, Gainotti S, Gussoni G. Decentralized clinical trials (DCTs): A few ethical considerations. *Front Public Health*. 2022;10:1081150. Published 2022 Dec 15. doi:10.3389/fpubh.2022.1081150
39. Merkel PA, Manion M, Gopal-Srivastava R, et al. The partnership of patient advocacy groups and clinical investigators in the rare diseases clinical research network. *Orphanet J Rare Dis*. 2016;11(1):66. Published 2016 May 18. doi:10.1186/s13023-016-0445-8
40. Sawesi S, Rashrash M, Phalakornkule K, Carpenter JS, Jones JF. The Impact of Information Technology on Patient Engagement and Health Behavior Change: A Systematic Review of the Literature. *JMIR Med Inform*. 2016;4(1):e1. Published 2016 Jan 21. doi:10.2196/medinform.4514